Apixaban*
-
API Product :
Apixaban*
-
CEP :
-
-
WCC :
?
-
Therapeutic Use :
Antithrombotic agents; Cardiac therapy
-
Originator :
Bristol-Myers Squibb
-
CAS No. :
503612-47-3
-
Trade Name. :
Eliquis
-
Molecular Weight :
459.497 g/mol
-
Molecular Formula :
C25H25N5O4
Application
Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. Withatrial fibrillation, part of the heart does not beat the way it should.
General Description
Apixaban, sold under the tradename Eliquis, is an anticoagulant for the treatment of venous thromboembolic events and the prevention of strokes in people who have atrial fibrillation. It is taken by mouth. It is a direct factor Xa inhibitor. Apixaban was approved in Europe in 2012.[1] It was approved in the U.S. in 2014 for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).[2] It was developed in a joint venture by Pfizer and Bristol-Myers Squibb. .